The notorious R.N.A. in the spotlight - drug or target for the treatment of disease

RNA Biology

Volumn 14, Issue 5, 2017, Pages 651-668

  Reautschnig, Philipp ^a   Vogel, Paul ^a   Stafforst, Thorsten ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Antisense oligonucleotide; chemically modified oligonucleotides; genetic disease; RNA interference; RNA repair; RNA vaccines; site directed RNA editing; splice switching oligonucleotide; therapeutic aptamer; therapeutic mRNA

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APTAMER; MESSENGER RNA; RIBONUCLEASE H; RNA; VACCINE; COMPLEMENTARY RNA;

ARTICLE; DESENSITIZATION; DRUG TARGETING; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RNA INTERFERENCE; RNA REPAIR; VACCINATION; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; GENETIC DISORDER; GENETICS; METABOLISM; RNA EDITING; RNA STABILITY; RNAI THERAPEUTICS;

APTAMERS, NUCLEOTIDE; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; GENETIC DISEASES, INBORN; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; RIBONUCLEASE H; RNA EDITING; RNA INTERFERENCE; RNA STABILITY; RNA, ANTISENSE; RNA, MESSENGER; RNAI THERAPEUTICS;

EID: 84982283717     PISSN: 15476286     EISSN: 15558584     Source Type: Journal    
DOI: 10.1080/15476286.2016.1208323     Document Type: Article

References (251)

1. Klungland A, Dahl JA. Dynamic RNA modifications in disease. Curr Opin Genet Dev 2014; 26:47-52; PMID:25005745; http://dx.doi.org/10.1016/j.gde.2014.05.006
2. Schoenberg DR, Maquat LE. Regulation of cytoplasmic mRNA decay. Nat Rev Genet 2012; 13:246-59; PMID:22392217; http://dx.doi.org/10.1038/nrg3254
3. Chabot B, Shkreta L. Defective control of pre-messenger RNA splicing in human disease. J Cell Biol 2016; 212:13-27; PMID:26728853; http://dx.doi.org/10.1083/jcb.201510032
4. Scheper GC, van der Knaap MS, Proud CG. Translation matters:protein synthesis defects in inherited disease. Nat Rev Genet 2007; 8:711-23; PMID:17680008; http://dx.doi.org/10.1038/nrg2142
5. Nalavade R, Griesche N, Ryan DP, Hildebrand S, Krauss S. Mechanisms of RNA-induced toxicity in CAG repeat disorders. Cell Death Dis 2013; 4:e752; PMID:23907466; http://dx.doi.org/10.1038/cddis.2013.276
6. Bennett CF, Swayze EE. RNA targeting therapeutics:molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010; 50:259-93; PMID:20055705; http://dx.doi.org/10.1146/annurev.pharmtox.010909.105654
7. Kole R, Krainer AR, Altman S. RNA therapeutics:beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 2012; 11:125-40; PMID:22262036; http:dx.doi.org/10.1038/nrd3625
8. Geary RS. Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol 2009; 5:381-91; PMID:19379126; http://dx.doi.org/10.1517/17425250902877680
9. Cox DB, Platt RJ, Zhang F. Therapeutic genome editing:prospects and challenges. Nat Med 2015; 21:121-31; PMID:25654603; http://dx.doi.org/10.1038/nm.3793
10. Myra Stern and Eric WFW Alton. Use of Liposomes in the Treatment of Cystic Fibrosis. Gene Therapy in Lung Disease CRC Press, 2002; 383–396; http://dx.doi.org/10.3109/9780203908822-18
11. Sehgal A, Barros S, Ivanciu L, Cooley B, Qin J, Racie T, Hettinger J, Carioto M, Jiang Y, Brodsky J, et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med 2015; 21:492-7; PMID:25849132; http://dx.doi.org/10.1038/nm.3847
12. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391:806-11; PMID:9486653; http://dx.doi.org/10.1038/35888
13. Wu H, Lima WF, Zhang H, Fan A, Sun H, Crooke ST. Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J Biol Chem 2004; 279:17181-9; PMID:14960586; http://dx.doi.org/10.1074/jbc.M311683200
14. Vitravene Study Group. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol 2002; 133:467-74; PMID:11931780; http://dx.doi.org/10.1016/S0002-9394(02)01327-2
15. Vitravene Study Group. Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS. Am J Ophthalmol 2002; 133:475-83; PMID:11931781; http://dx.doi.org/10.1016/S0002-9394(02)01326-0
16. Vitravene Study Group. Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol 2002; 133:484-98; PMID:11931782; http://dx.doi.org/10.1016/S0002-9394(02)01332-6
17. Greuter T, Biedermann L, Rogler G, Sauter B, Seibold F. Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy:A case series. United European Gastroenterol J 2016; 4:97-104; PMID:26966529; http://dx.doi.org/10.1177/2050640615593681
18. Randomized Study of Topical Alicaforsen Enema in Antibiotic Refractory Pouchitis. (2015). Clinical Phase Trial III
19. Cloutier F, Lawrence M, Goody R, Lamoureux S, Al-Mahmood S, Colin S, Ferry A, Conduzorgues JP, Hadri A, Cursiefen C, et al. Antiangiogenic activity of aganirsen in nonhuman primate and rodent models of retinal neovascular disease after topical administration. Invest Ophthalmol Vis Sci 2012; 53:1195-203; PMID:22323484; http://dx.doi.org/10.1167/iovs.11-9064
20. Cursiefen C, Viaud E, Bock F, Geudelin B, Ferry A, Kadlecová P, Lévy M, Al Mahmood S, Colin S, Thorin E, et al. Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation:the I-CAN study. Ophthalmology 2014; 121:1683-92; PMID:24811963; http://dx.doi.org/10.1016/j.ophtha.2014.03.038
21. A multicentre double-blind randomized study to investigate the efficacy and tolerability of GS-101 eye drops, an antisense oligonucleotide, versus placebo on inhibition of corneal neovascularization, a major risk factor of corneal graft rejection:The I-GRAFT study. (2009). Clinical Trial Phase III
22. The STRONG Study. (http://strong-nvg.com/the-study/). Clinical Trial Phase II/III
23. Yoon H, Kim DJ, Ahn EH, Gellert GC, Shay JW, Ahn CH, Lee YB. Antitumor activity of a novel antisense oligonucleotide against Akt1. J Cell Biochem 2009; 108:832-8; PMID:19693774; http://dx.doi.org/10.1002/jcb.22311
24. A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer. (2009). Clinical Trial Phase II
25. Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer. (2014). Clinical Trial Phase IB/II
26. Tagawa ST, Chatta GS, Mazhari R, Benaim E. Archexin, a novel AKT-1-specific inhibitor for the treatment of metastatic renal cancer:Preliminary phase I data. ASCO Annual Meeting Proceedings 2016; (suppl 2S; abstr 550);
27. MacLeod AR. Antisense therapies for cancer:bridging the pharmacogenomic divide. Drug Discovery Today:Therapeutic Strategies 2013; 10:e157-e63
28. Teplova M, Minasov G, Tereshko V, Inamati GB, Cook PD, Manoharan M, Egli M. Crystal structure and improved antisense properties of 2′-O-(2-methoxyethyl)-RNA. Nat Struct Mol Biol 1999; 6:535-9; PMID:10360355; http://dx.doi.org/10.1038/9304.
29. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng M-J, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia:a randomised, double-blind, placebo-controlled trial. The Lancet 2010; 375:998-1006; http://dx.doi.org/10.1016/S0140-6736(10)60284-X
30. Stein EA, Dufour R, Gagne C, Gaudet D, East C, Donovan JM, Chin W, Tribble DL, McGowan M. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia:results of a randomized, double-blind, placebo controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012; 126:2283-92; PMID:23060426; http://dx.doi.org/10.1161/CIRCULATIONAHA.112.104125
31. Santos RD, Duell PB, East C, Guyton JR, Moriarty PM, Chin W, Mittleman RS. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia:2-year interim results of an open-label extension. Eur Heart J 2015; 36:566-75; PMID:24366918; http://dx.doi.org/10.1093/eurheartj/eht549
32. Ackermann EJ, Guo S, Booten S, Alvarado L, Benson M, Hughes S, Monia BP. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 2012; 19:43-4; PMID:22494066; http://dx.doi.org/10.3109/13506129.2012.673140
33. Efficacy and Safety of IONIS-TTR Rx in Familial Amyloid Polyneuropathy. (2012). Clinical Phase trial II/III
34. Open-Label Extension Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP). (2012). Clinical Phase Trial III
35. Ionis Pharmaceuticals Press Release. (http://ir.isispharm.com/phoenix.zhtml?c=222170&p=irol-newsArticle&ID2105651). 2015
36. Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer (SYNERGY). (2010). Clinical Trial Phase III
37. Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer (AFFINITY). (2012). Clinical Trial Phase III
38. OncoGenex Press Release. (http://ir.oncogenex.com/releasedetail.cfm?ReleaseID=933276). 2015
39. Laskin JJ, Nicholas G, Lee C, Gitlitz B, Vincent M, Cormier Y, Stephenson J, Ung Y, Sanborn R, Pressnail B, et al. Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. J Thorac Oncol 2012; 7:579-86; PMID:22198426; http://dx.doi.org/10.1097/JTO.0b013e31823f459c
40. A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer. (2012). Clinical Trial Phase III
41. Seth PP, Vasquez G, Allerson CA, Berdeja A, Gaus H, Kinberger GA, Prakash TP, Migawa MT, Bhat B, Swayze EE. Synthesis and biophysical evaluation of 2′, 4′-constrained 2′ O-methoxyethyl and 2′, 4′-constrained 2′ O-ethyl nucleic acid analogues. J Org Chem 2010; 75:1569-81; PMID:20136157; http://dx.doi.org/10.1021/jo902560f
42. Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Translat Med 2015; 7:314ra185-314ra185; http://dx.doi.org/10.1126/scitranslmed.aac5272
43. AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites. (2015). Clinical Trial Phase II
44. Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck. (2015). Clinical Trial Phase IB/II
45. Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers. (2012). Clinical Trial Phase I/II
46. MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Diffuse Large B-cell Lymphoma (D4190C00023). (2015). Clinical Trial Phase IB
47. Prakash PT, Seth PP, Swayze EE, Graham MJ. Compositions and methods for modulating apolipoprotein (a) expression (US. Patent No. Nine,181,550). 2015
48. Nair JK, Willoughby JL, Chan A, Charisse K, Alam MR, Wang Q, Hoekstra M, Kandasamy P, Kel'in AV, Milstein S, et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc 2014; 136:16958-61; PMID:25434769; http://dx.doi.org/10.1021/ja505986a
49. Prakash TP, Graham MJ, Yu J, Carty R, Low A, Chappell A, Schmidt K, Zhao C, Aghajan M, Murray HF, et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res 2014; 42:8796-807; PMID:24992960; http://dx.doi.org/10.1093/nar/gku531
50. Ionis Pharmaceuticals Press Release. (http://ir.isispharm.com/phoenix.zhtml?c=222170&p=irol-newsArticle&ID=2110180) 2015
51. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a). (2015). Clinical Trial Phase I
52. Hoffman EP, Brown RH, Kunkel LM. Dystrophin:the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51:919-28; PMID:3319190; http://dx.doi.org/10.1016/0092-8674(87)90579-4
53. Aartsma‐Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen GJ, den Dunnen JT. Theoretic applicability of antisense‐mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 2009; 30:293-9; PMID:19156838; http://dx.doi.org/10.1002/humu.20918
54. Koenig M, Beggs A, Moyer M, Scherpf S, Heindrich K, Bettecken T, Meng G, Müller CR, Lindlöf M, Kaariainen H, et al. The molecular basis for Duchenne versus Becker muscular dystrophy:correlation of severity with type of deletion. Am J Hum Genet 1989; 45:498; PMID:2491009
55. Voit T, Topaloglu H, Straub V, Muntoni F, Deconinck N, Campion G, De Kimpe SJ, Eagle M, Guglieri M, Hood S, et al. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II):an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol 2014; 13:987-96; PMID:25209738; http://dx.doi.org/10.1016/S1474-4422(14)70195-4
56. A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian Subjects. (2013). Clinical Trial Phase III
57. Extension Study of Drisapersen in DMD Subjects. (2015). Clinical Trial Phase IIIB
58. Mendell JR, Rodino‐Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, Alfano L, Gomez AM, Lewis S, Kota J, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 2013; 74:637-47; PMID:23907995; http://dx.doi.org/10.1002/ana.23982
59. Confirmatory Study of Eteplirsen in DMD Patients (PROMOVI). (2014). Clinical Trial Phase III
60. Drisapersen FDA Report. (http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM473737.pdf). 2015
61. Komaki H, Nagata T, Saito T, Masuda S, Takeshita E, Tachimori H, et al. GP 251-Exon 53 skipping of the dystrophin gene in patients with Duchenne muscular dystrophy by systemic administration of NS-065/NCNP-01:A phase 1, dose escalation, first-in-human study. Neuromuscular Disorders 2015; 25:S261-S2; http://dx.doi.org/10.1016/j.nmd.2015.06.276
62. Nippon Shinyaku Press Release. (https://www.nippon-shinyaku.co.jp/english/news/?id=2920). 2016
63. Koizumi M. 2′-O, 4′-C-Ethylene-bridged nucleic acids (ENA) as next-generation antisense and antigene agents. Biol Pharm Bull 2004; 27:453-6; PMID:15056846; http://dx.doi.org/10.1248/bpb.27.453
64. Daiichi Sankyo Press Release. (http://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006412/160225_635_E.pdf). 2016
65. Study of DS-5141b in Patients With Duchenne Muscular Dystrophy. (2016). Clinical Trial Phase I/II
66. Lefebvre S, Bürglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995; 80:155-65; PMID:7813012; http://dx.doi.org/10.1016/0092-8674(95)90460-3
67. Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A 1999; 96:6307-11; PMID:103395583; http://dx.doi.org/10.1073/pnas.96.11.6307
68. Hua Y, Vickers TA, Okunola HL, Bennett CF, Krainer AR. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet 2008; 82:834-48; PMID:18371932; http://dx.doi.org/10.1016/j.ajhg.2008.01.014
69. Ionis Pharmaceuticals. (http://ir.ionispharma.com/phoenix.zhtml?c=222170&p=irol-newsArticle&ID=2097778). 2015
70. A Study to Assess the Efficacy and Safety of IONIS-SMN Rx in Infants With Spinal Muscular Atrophy. (2014). Clinical Trial Phase III
71. A Study to Assess the Efficacy and Safety of IONIS-SMN Rx in Patients With Later-onset Spinal Muscular Atrophy. (2014). Clinical Phase Trial III
72. Disterer P, Kryczka A, Liu Y, Badi YE, Wong JJ, Owen JS, Khoo B. Development of therapeutic splice-switching oligonucleotides. Hum Gene Ther 2014; 25:587-98; PMID:24826963; http://dx.doi.org/10.1089/hum.2013.234
73. Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov 2010; 9:537-50; PMID:20592747; http://dx.doi.org/10.1038/nrd3141
74. Bouchard PR, Hutabarat RM, Thompson KM. Discovery and Development of Therapeutic Aptamers. Annu Rev Pharmacol Toxicol 2010; 50:237-57; PMID:20055704; http://dx.doi.org/10.1146/annurev.pharmtox.010909.105547
75. Ruckman J, Green LS, Beeson J, Waugh S, Gillette WL, Henninger DD, Claesson-Welsh L, Janjić N. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 1998; 273:20556-67; PMID:9685413; http://dx.doi.org/10.1074/jbc.273.32.20556
76. Ng EWM, Shima DT, Calias P, Cunningham ET, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006; 5:123-32; PMID:16518379; http://dx.doi.org/10.1038/nrd1955
77. Lincoff AM, Mehran R, Povsic TJ, Zelenkofske SL, Huang Z, Armstrong PW, Steg PG, Bode C, Cohen MG, Buller C, et al. Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI):a randomised clinical trial. Lancet 2016; 387:349-56; PMID:26547100; http://dx.doi.org/10.1016/S0140-6736(15)00515-2
78. A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI (Regulate). (2013). Clinical Trial Phase III (Terminated)
79. Dugel PU. Anti-PDGF combination therapy in neovascular age-related macular degeneration:results of a phase 2b study. Retina Today 2013; 8:65-71
80. A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy. (2013). Clinical Trial Phase III
81. A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy. (2013). Clinical Trial Phase III
82. Monés J. Complement factor 5 inhibition in age-related macular degeneration. Retina Today 2010; 5:52-5
83. A Phase 2/3 Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura® (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration. (2016). Clinical Trial Phase II/III
84. Vater A, Klussmann S. Turning mirror-image oligonucleotides into drugs:the evolution of Spiegelmer® therapeutics. Drug Discovery Today 2015; 20:147-55; PMID:25236655; http://dx.doi.org/10.1016/j.drudis.2014.09.004
85. Ashley GW. Modeling, synthesis, and hybridization properties of (L)-ribonucleic acid. J Am Chem Soc 1992; 114:9731-6; http://dx.doi.org/10.1021/ja00051a001
86. van Eijk LT, John AS, Schwoebel F, Summo L, Vauléon S, Zöllner S, Laarakkers CM, Kox M, van der Hoeven JG, Swinkels DW, et al. Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans. Blood 2014; 124:2643-6; PMID:25163699; http://dx.doi.org/10.1182/blood-2014-03-559484
87. Roccaro AM, Sacco A, Purschke WG, Moschetta M, Buchner K, Maasch C, Zboralski D, Zöllner S, Vonhoff S, Mishima Y, et al. SDF-1 inhibition targets the bone marrow niche for cancer therapy. Cell Rep 2014; 9:118-28; PMID:25263552; http://dx.doi.org/10.1016/j.celrep.2014.08.042
88. NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma. (2012). Clinical Trial Phase IIA
89. NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL). (2011). Clinical Trial Phase IIA
90. Oberthür D, Achenbach J, Gabdulkhakov A, Buchner K, Maasch C, Falke S, Rehders D, Klussmann S, Betzel C. Crystal structure of a mirror-image L-RNA aptamer (Spiegelmer) in complex with the natural L-protein target CCL2. Nat Commun 2015; 6:6923; PMID:25901662; http://dx.doi.org/10.1038/ncomms7923
91. NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria. (2012). Clinical Trial Phase IIA
92. Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer. (2012). Clinical Trial Phase IIA
93. MacRae IJ, Ma E, Zhou M, Robinson CV, Doudna JA. In vitro reconstitution of the human RISC-loading complex. Proc Natl Acad Sci U S A 2008; 105:512-7; PMID:18178619; http://dx.doi.org/10.1073/pnas.0710869105
94. Valinezhad Orang A, Safaralizadeh R, Kazemzadeh-Bavili M. Mechanisms of miRNA-Mediated Gene Regulation from Common Downregulation to mRNA-Specific Upregulation. Int J Genomics 2014; 2014:970607; PMID:25180174
95. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411:494-8; PMID:11373684; http://dx.doi.org/10.1038/35078107
96. Mellitzer G, Hallonet M, Chen L, Ang SL. Spatial and temporal ‘knock down’ of gene expression by electroporation of double-stranded RNA and morpholinos into early postimplantation mouse embryos. Mech Dev 2002; 118:57-63; PMID:12351170; http://dx.doi.org/10.1016/S0925-4773(02)00191-0
97. Calegari F, Haubensak W, Yang D, Huttner WB, Buchholz F. Tissue-specific RNA interference in postimplantation mouse embryos with endoribonuclease-prepared short interfering RNA. Proc Natl Acad Sci U S A 2002; 99:14236-40; PMID:12391321; http://dx.doi.org/10.1073/pnas.192559699
98. Zeliadt N. Big pharma shows signs of renewed interest in RNAi drugs. Nat Med 2014; 20:109; PMID:24504395; http://dx.doi.org/10.1038/nm0214-109
99. Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5. (2004). Clinical Trial Phase I
100. A Dose Escalation and Safety Study of I5NP to Prevent Acute Kidney Injury (AKI) in Patients at High Risk of AKI Undergoing Major Cardiovascular Surgery (QRK.004). (2008). Clinical Trial Phase I (Terminated)
101. Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (COBALT). (2007). Clinical Trial Phase III (Terminated)
102. Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema (DEGAS). (2008). Clinical Trial Phase II (Terminated)
103. Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol. (2009). Clinical Trial Phase I (Terminated)
104. A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration. (2006). Clinical Trial Phase II (Terminated)
105. Conde J, Artzi N. Are RNAi and miRNA therapeutics truly dead? Trends Biotechnol 2015; 33:141-4; PMID:25595555; http://dx.doi.org/10.1016/j.tibtech.2014.12.005
106. Krieg AM. Is RNAi dead? Mol Ther 2011; 19:1001-2; PMID:21629254; http://dx.doi.org/10.1038/mt.2011.94
107. Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, Perez J, Chiesa J, Warrington S, Tranter E, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013; 369:819-29; PMID:23984729; http://dx.doi.org/10.1056/NEJMoa1208760
108. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, Liebow A, Bettencourt BR, Sutherland JE, Hutabarat RM, Clausen VA, Karsten V, Cehelsky J, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers:a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 2014; 383:60-8; PMID:24094767; http://dx.doi.org/10.1016/S0140-6736(13)61914-5
109. van de Water FM, Boerman OC, Wouterse AC, Peters JG, Russel FG, Masereeuw R. Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos 2006; 34:1393-7; PMID:16714375; http://dx.doi.org/10.1124/dmd.106.009555
110. Alagia A, Eritja R. siRNA and RNAi optimization. Wiley interdisciplinary reviews RNA, 2016 7; 316-329; PMID:26840434; http://dx.doi.org/10.1002/wrna.1337
111. Lorenzer C, Dirin M, Winkler AM, Baumann V, Winkler J. Going beyond the liver:progress and challenges of targeted delivery of siRNA therapeutics. J Control Release 2015; 203:1-15; PMID:25660205; http://dx.doi.org/10.1016/j.jconrel.2015.02.003
112. Jeong EH, Kim H, Jang B, Cho H, Ryu J, Kim B, Park Y, Kim J, Lee JB, Lee H. Technological development of structural DNA/RNA-based RNAi systems and their applications. Adv Drug Deliv Rev 2016; 107:29-43; PMID:26494399; http://dx.doi.org/10.1016/j.addr.2015.10.008
113. Bramsen JB, Kjems J. Engineering small interfering RNAs by strategic chemical modification. Methods Mol Biol 2013; 942:87-109; PMID:23027047; http://dx.doi.org/10.1007/978-1-62703-119-6_5
114. Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4). (2014). Clinical Trial Phase I
115. Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy. (2015). Clinical Trial Phase II
116. A Phase 1 Study of ALN-AS1 in Patients With Acute Intermittent Porphyria (AIP). (2015). Clinical Trial Phase I
117. ENDEAVOUR:Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC). (2014). Clinical Trial Phase III
118. A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients. (2014). Clinical Trial Phase I
119. Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer (STMN1-LP). (2012). Clinical Trial Phase I
120. APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery. (2014). Clinical Trial Phase I
121. SYL040012, Treatment for Open Angle Glaucoma (SYLTAG). (2014). Clinical Trial Phase II
122. Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION). (2015). Clinical Trial Phase II/III
123. Bobbin ML, Rossi JJ. RNA Interference (RNAi)-Based Therapeutics:Delivering on the Promise? Annu Rev Pharmacol Toxicol 2016; 56:103-22; PMID:26738473; http://dx.doi.org/10.1146/annurev-pharmtox-010715-103633
124. Lam JK, Chow MY, Zhang Y, Leung SW. siRNA Versus miRNA as Therapeutics for Gene Silencing. Mol Ther Nucleic Acids 2015; 4:e252; PMID:26372022; http://dx.doi.org/10.1038/mtna.2015.23
125. Long-term Extension to Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C. (2014). Clinical Trial Phase II
126. Lee CH, Kim JH, Lee SW. The role of microRNAs in hepatitis C virus replication and related liver diseases. J Microbiol 2014; 52:445-51; PMID:24871972; http://dx.doi.org/10.1007/s12275-014-4267-x
127. MesomiR 1:A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC. (2015). Clinical Trial Phase I
128. A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection. (2013). Clinical Trial Phase I
129. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. Science 1990; 247:1465-8; PMID:1690918; http://dx.doi.org/10.1126/science.1690918
130. Jirikowski GF, Sanna PP, Maciejewski-Lenoir D, Bloom FE. Reversal of diabetes insipidus in Brattleboro rats:intrahypothalamic injection of vasopressin mRNA. Science 1992; 255:996-8; PMID:1546298; http://dx.doi.org/10.1126/science.1546298
131. Isaacs A, Cox RA, Rotem Z. Foreign nucleic acids as the stimulus to make interferon. Lancet 1963; 2:113-6; PMID:13956740; http://dx.doi.org/10.1016/S0140-6736(63)92585-6
132. Weissman D. mRNA transcript therapy. Expert Rev Vaccines 2015; 14:265-81; PMID:25359562; http://dx.doi.org/10.1586/14760584.2015.973859
133. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413:732-8; PMID:11607032; http://dx.doi.org/10.1038/35099560
134. Anderson BR, Muramatsu H, Nallagatla SR, Bevilacqua PC, Sansing LH, Weissman D, Karikó K. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res 2010; 38:5884-92; PMID:20457754; http://dx.doi.org/10.1093/nar/gkq347
135. Kariko K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, Weissman D. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 2008; 16:1833-40; PMID:18797453; http://dx.doi.org/10.1038/mt.2008.200
136. Goubau D, Deddouche S, Reis e Sousa C. Cytosolic sensing of viruses. Immunity 2013; 38:855-69; PMID:23706667; http://dx.doi.org/10.1016/j.immuni.2013.05.007
137. Kariko K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors:the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005; 23:165-75; PMID:16111635; http://dx.doi.org/10.1016/j.immuni.2005.06.008
138. Kormann MS, Hasenpusch G, Aneja MK, Nica G, Flemmer AW, Herber-Jonat S, Huppmann M, Mays LE, Illenyi M, Schams A, et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol 2011; 29:154-7; PMID:21217696; http://dx.doi.org/10.1038/nbt.1733
139. Karijolich J, Yu YT. Converting nonsense codons into sense codons by targeted pseudouridylation. Nature 2011; 474:395-8; PMID:21677757; http://dx.doi.org/10.1038/nature10165
140. Summer H, Gramer R, Droge P. Denaturing urea polyacrylamide gel electrophoresis (Urea PAGE). J Vis Exp 2009; PMID:19865070; http://dx.doi.org/10.3791/1485(2009)
141. Kariko K, Muramatsu H, Ludwig J, Weissman D. Generating the optimal mRNA for therapy:HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res 2011; 39:e142; PMID:21890902; http://dx.doi.org/10.1093/nar/gkr695
142. Pasquinelli AE, Dahlberg JE, Lund E. Reverse 5' caps in RNAs made in vitro by phage RNA polymerases. RNA 1995; 1:957-67; PMID:8548660
143. Stepinski J, Waddell C, Stolarski R, Darzynkiewicz E, Rhoads RE. Synthesis and properties of mRNAs containing the novel “anti-reverse” cap analogs 7-methyl(3'-O-methyl)GpppG and 7-methyl (3'-deoxy)GpppG. RNA 2001; 7:1486-95; PMID:11680853; http://dx.doi.org/10.1017.S1355838201014078
144. Grudzien-Nogalska E, Jemielity J, Kowalska J, Darzynkiewicz E, Rhoads RE. Phosphorothioate cap analogs stabilize mRNA and increase translational efficiency in mammalian cells. RNA 2007; 13:1745-55; PMID:17720878; http://dx.doi.org/10.1261/rna.701307
145. Fath S, Bauer AP, Liss M, Spriestersbach A, Maertens B, Hahn P, Ludwig C, Schäfer F, Graf M, Wagner R. Multiparameter RNA and codon optimization:a standardized tool to assess and enhance autologous mammalian gene expression. PLoS one 2011; 6:e17596; PMID:21408612; http://dx.doi.org/10.1371/journal.pone.0017596
146. Al-Saif M, Khabar KS. UU/UA dinucleotide frequency reduction in coding regions results in increased mRNA stability and protein expression. Mol Ther 2012; 20:954-9; PMID:22434136; http://dx.doi.org/10.1038/mt.2012.29
147. Weissman D, Kariko K. mRNA:Fulfilling the Promise of Gene Therapy. Mol Ther 2015; 23:1416-7; PMID:26321183; http://dx.doi.org/10.1038/mt.2015.138
148. Zubiaga AM, Belasco JG, Greenberg ME. The nonamer UUAUUUAUU is the key AU-rich sequence motif that mediates mRNA degradation. Mol Cell Biol 1995; 15:2219-30; PMID:7891716; http://dx.doi.org/10.1128/MCB.15.4.2219
149. Peixeiro I, Silva AL, Romao L. Control of human β-globin mRNA stability and its impact on β-thalassemia phenotype. Haematologica 2011; 96:905-13; PMID:21357703; http://dx.doi.org/10.3324/haematol.2010.039206
150. Waggoner SA, Liebhaber SA. Regulation of α-globin mRNA stability. Exp Biol Med (Maywood) 2003; 228:387-95; PMID:12671183
151. Withers JB, Beemon KL. The structure and function of the rous sarcoma virus RNA stability element. J Cell Biochem 2011; 112:3085-92; PMID:21769913; http://dx.doi.org/10.1002/jcb.23272
152. Gallie DR. The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency. Genes Dev 1991; 5:2108-16; PMID:1682219; http://dx.doi.org/10.1101/gad.5.11.2108
153. Peng J, Murray EL, Schoenberg DR. In vivo and in vitro analysis of poly(A) length effects on mRNA translation. Methods Mol Biol 2008; 419:215-30; PMID:18369986; http://dx.doi.org/10.1007/978-1-59745-033-1_15
154. Balmayor ER, Geiger JP, Aneja MK, Berezhanskyy T, Utzinger M, Mykhaylyk O, Rudolph C, Plank C. Chemically modified RNA induces osteogenesis of stem cells and human tissue explants as well as accelerates bone healing in rats. Biomaterials 2016; 87:131-46; PMID:26923361; http://dx.doi.org/10.1016/j.biomaterials.2016.02.018
155. Elangovan S, Khorsand B, Do AV, Hong L, Dewerth A, Kormann M, Ross RD, Sumner DR, Allamargot C, Salem AK. Chemically modified RNA activated matrices enhance bone regeneration. J Control Release 2015; 218:22-8; PMID:26415855; http://dx.doi.org/10.1016/j.jconrel.2015.09.050
156. Plews JR, Li J, Jones M, Moore HD, Mason C, Andrews PW, Na J. Activation of pluripotency genes in human fibroblast cells by a novel mRNA based approach. PloS one 2010; 5:e14397; PMID:21209933; http://dx.doi.org/10.1371/journal.pone.0014397
157. Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, Ebina W, Mandal PK, Smith ZD, Meissner A, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010; 7:618-30; PMID:20888316; http://dx.doi.org/10.1016/j.stem.2010.08.012
158. Mandal PK, Rossi DJ. Reprogramming human fibroblasts to pluripotency using modified mRNA. Nat Protoc 2013; 8:568-82; PMID:23429718; http://dx.doi.org/10.1038/nprot.2013.019
159. Preskey D, Allison TF, Jones M, Mamchaoui K, Unger C. Synthetically modified mRNA for efficient and fast human iPS cell generation and direct transdifferentiation to myoblasts. Biochem Biophys Res Commun 2015; PMID:26449459; http://dx.doi.org/10.1016/j.bbrc.2015.09.102
160. Simeonov KP, Uppal H. Direct reprogramming of human fibroblasts to hepatocyte-like cells by synthetic modified mRNAs. PloS One 2014; 9:e100134; PMID:24963715; http://dx.doi.org/10.1371/journal.pone.0100134
161. Kariko K, Muramatsu H, Keller JM, Weissman D. Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin. Mol Ther 2012; 20:948-53; PMID:22334017; http://dx.doi.org/10.1038/mt.2012.7
162. Yin H, Xue W, Chen S, Bogorad RL, Benedetti E, Grompe M, Koteliansky V, Sharp PA, Jacks T, Anderson DG. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 2014; 32:551-3; PMID:24681508; http://dx.doi.org/10.1038/nbt.2884
163. Wang X, Yu H, Lei A, Zhou J, Zeng W, Zhu H, Niu Y, Shi B, Cai B, Liu J, et al. Generation of gene-modified goats targeting MSTN and FGF5 via zygote injection of CRISPR/Cas9 system. Sci Rep 2015; 5:13878; PMID:26354037; http://dx.doi.org/10.1038/srep13878
164. Kaneko T, Mashimo T. Simple Genome Editing of Rodent Intact Embryos by Electroporation. PloS one 2015; 10:e0142755; PMID:26556280; http://dx.doi.org/10.1371/journal.pone.0142755
165. Wang T, Hong Y. Direct gene disruption by TALENs in medaka embryos. Gene 2014; 543:28-33; PMID:24713411; http://dx.doi.org/10.1016/j.gene.2014.04.013
166. Yang D, Zhang J, Xu J, Zhu T, Fan Y, Fan J, Chen YE. Production of apolipoprotein C-III knockout rabbits using zinc finger nucleases. J Vis Exp 2013; 81; e50957; PMID:24301055; http://dx.doi.org/10.3791/50957
167. Flisikowska T, Thorey IS, Offner S, Ros F, Lifke V, Zeitler B, Rottmann O, Vincent A, Zhang L, Jenkins S, et al. Efficient immunoglobulin gene disruption and targeted replacement in rabbit using zinc finger nucleases. PloS One 2011; 6:e21045; PMID:21695153; http://dx.doi.org/10.1371/journal.pone.0021045
168. Williams DA, Thrasher AJ. Concise review:lessons learned from clinical trials of gene therapy in monogenic immunodeficiency diseases. Stem Cells Transl Med 2014; 3:636-42; PMID:24682287; http://dx.doi.org/10.5966/sctm.2013-0206
169. Schirmbeck R, Reimann J, Kochanek S, Kreppel F. The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens. Mol Ther 2008; 16:1609-16; PMID:18612271; http://dx.doi.org/10.1038/mt.2008.141
170. Mahiny AJ, Dewerth A, Mays LE, Alkhaled M, Mothes B, Malaeksefat E, Loretz B, Rottenberger J, Brosch DM, Reautschnig P, et al. In vivo genome editing using nuclease-encoding mRNA corrects SP-B deficiency. Nat Biotechnol 2015; 33:584-6; PMID:25985262; http://dx.doi.or/10.1038/nbt.3241
171. Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, Schneider T. Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 2011; 117:2791-9; PMID:21148083; http://dx.doi.org/10.1182/blood-2010-09-309591
172. Evaluation the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma (Lipo-MERIT). (2015). Clinical Trial Phase I
173. Wissink EM, Fogarty EA, Grimson A. High-throughput discovery of post-transcriptional cis-regulatory elements. BMC Genomics 2016; 17:177; PMID:26941072; http://dx.doi.org/10.1186/s12864-016-2479-7
174. Desmet CJ, Ishii KJ. Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol 2012; 12:479-91; PMID:22728526; http://dx.doi.org/10.1038/nri3247
175. Brubaker SW, Bonham KS, Zanoni I, Kagan JC. Innate immune pattern recognition:a cell biological perspective. Annu Rev Immunol 2015; 33:257-90; PMID:25581309; http://dx.doi.org/10.1146/annurev-immunol-032414-112240
176. Clark GJ, Angel N, Kato M, Lopez JA, MacDonald K, Vuckovic S, Hart DN. The role of dendritic cells in the innate immune system. Microbes Infect 2000; 2:257-72; PMID:10758402; http://dx.doi.org/10.1016/S1286-4579(00)00302-6
177. Jacobson JM, Routy JP, Welles S, DeBenedette M, Tcherepanova I, Angel JB, Asmuth DM, Stein DK, Baril JG, McKellar M, et al. Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA:A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. J Acquir Immune Defic Syndr 2016; 72:31-8; PMID:26751016; http://dx.doi.org/10.1097/QAI.0000000000000926
178. Weiss R, Scheiblhofer S, Thalhamer J. Allergens are not pathogens:why immunization against allergy differs from vaccination against infectious diseases. Hum Vaccin Immunother 2014; 10:703-7; PMID:24280693; http://dx.doi.org/10.4161/hv.27183
179. Weiss R, Scheiblhofer S, Roesler E, Ferreira F, Thalhamer J. Prophylactic mRNA vaccination against allergy. Curr Opin Allergy Clin Immunol 2010; 10:567-74; PMID:20856111; http://dx.doi.org/10.1097/ACI.0b013e32833fd5b6
180. Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojkic-Zrna S, Probst J, Kallen KJ. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 2011; 34:1-15; PMID:21150709; http://dx.doi.org/10.1097/CJI.0b013e3181f7dbe8
181. Fotin-Mleczek M, Zanzinger K, Heidenreich R, Lorenz C, Kowalczyk A, Kallen KJ, et al. mRNA-based vaccines synergize with radiation therapy to eradicate established tumors. Radiat Oncol 2014; 9:180; PMID:25127546; http://dx.doi.org/10.1186/1748-717X-9-180
182. Schmidt MA, Goodwin TJ. Personalized medicine in human space flight:using Omics based analyses to develop individualized countermeasures that enhance astronaut safety and performance. Metabolomics 2013; 9:1134-56; PMID:24273472; http://dx.doi.org/10.1007/s11306-013-0556-3
183. Petsch B, Schnee M, Vogel AB, Lange E, Hoffmann B, Voss D, Schlake T, Thess A, Kallen KJ, Stitz L, et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 2012; 30:1210-6; PMID:23159882; http://dx.doi.org/10.1038/nbt.2436
184. Pascolo S. Vaccination with messenger RNA. Methods Mol Med 2006; 127:23-40; PMID:16988444; htpp://dx.doi.org/10.1385/1-59745-168-1:23
185. Mortimer I, Tam P, MacLachlan I, Graham RW, Saravolac EG, Joshi PB. Cationic lipid-mediated transfection of cells in culture requires mitotic activity. Gene Ther 1999; 6:403-11; PMID:10435090; http://dx.doi.org/10.1038/sj.gt.3300837
186. Wong SS, Webby RJ. An mRNA vaccine for influenza. Nat Biotechnol 2012; 30:1202-4; PMID:23222788; http://dx.doi.org/10.1038/nbt.2439
187. Ichino M, Mor G, Conover J, Weiss WR, Takeno M, Ishii KJ, Klinman DM. Factors associated with the development of neonatal tolerance after the administration of a plasmid DNA vaccine. J Immunol 1999; 162:3814-8; PMID:10201898
188. Ponsaerts P, Van Tendeloo VF, Berneman ZN. Cancer immunotherapy using RNA-loaded dendritic cells. Clin Exp Immunol 2003; 134:378-84; PMID:14632740; http://dx.doi.org/10.1046/j.1365-2249.2003.02286.x
189. Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tonnesen P, Suso EM, Sæbøe-Larssen S, Sandberg C, Brinchmann JE, Helseth E, et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother 2013; 62:1499-509; PMID:23817721; http://dx.doi.org/10.1007/s00262-013-1453-3
190. Van Gulck E, Vlieghe E, Vekemans M, Van Tendeloo VF, Van De Velde A, Smits E, Anguille S, Cools N, Goossens H, Mertens L, et al. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. AIDS 2012; 26:F1-12; PMID:22156965; http://dx.doi.org/10.1097/QAD.0b013e32834f33e8
191. Aarntzen EH, Schreibelt G, Bol K, Lesterhuis WJ, Croockewit AJ, de Wilt JH, van Rossum MM, Blokx WA, Jacobs JF, Duiveman-de Boer T, et al. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin Cancer Res 2012; 18:5460-70; PMID:22896657; http://dx.doi.org/10.1158/1078-0432.CCR-11-3368
192. Suso EM, Dueland S, Rasmussen AM, Vetrhus T, Aamdal S, Kvalheim G, Gaudernack G. hTERT mRNA dendritic cell vaccination:complete response in a pancreatic cancer patient associated with response against several hTERT epitopes. Cancer Immunol Immunother 2011; 60:809-18; PMID:21365467; http://dx.doi.org/10.1007/s00262-011-0991-9
193. Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K, Gostick E, Vermeulen K, Pieters K, Nijs G, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A 2010; 107:13824-9; PMID:20631300; http://dx.doi.org/10.1073/pnas.1008051107
194. Routy JP, Boulassel MR, Yassine-Diab B, Nicolette C, Healey D, Jain R, Landry C, Yegorov O, Tcherepanova I, Monesmith T, et al. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin Immunol 2010; 134:140-7; PMID:19889582; http://dx.doi.org/10.1016/j.clim.2009.09.009
195. Coosemans A, Wolfl M, Berneman ZN, Van Tendeloo V, Vergote I, Amant F, Van Gool SW. Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma. Anticancer Res 2010; 30:3709-14; PMID:20944158
196. Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC) (ADAPT). (2012). Clinical Trial Phase III
197. Wilgenhof S, Corthals J, Heirman C, van Baren N, Lucas S, Kvistborg P, Thielemans K, Neyns B. Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma. J Clin Oncol 2016; 34:1330-8; PMID:26926680; http://dx.doi.org/10.1200/JCO.2015.63.4121
198. Bol KF, Figdor CG, Aarntzen EH, Welzen ME, van Rossum MM, Blokx WA, van de Rakt MW, Scharenborg NM, de Boer AJ, Pots JM, et al. Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients. Oncoimmunology 2015; 4:e1019197; PMID:26405571; http://dx.doi.org/10.1080/2162402X.2015.1019197
199. MiHA-loaded PD-L-silenced DC Vaccination After Allogeneic SCT (PSCT19). (2016). Clinical Trial Phase II
200. Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients (ADDIT-GLIO). (2016). Clinical Trial Phase II
201. Autologous Dendritic Cell Vaccination in Mesothelioma (MESODEC). (2016). Clinical Trial Phase II
202. Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme (ATTAC-II). (2016). Clinical Trial Phase II
203. Weide B, Pascolo S, Scheel B, Derhovanessian E, Pflugfelder A, Eigentler TK, Pawelec G, Hoerr I, Rammensee HG, Garbe C. Direct injection of protamine-protected mRNA:results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother 2009; 32:498-507; PMID:19609242; http://dx.doi.org/10.1097/CJI.0b013e3181a00068
204. RNActive® Rabies Vaccine (CV7201) in Healthy Adults. (2014). Clinical Trial Phase I
205. Hekele A, Bertholet S, Archer J, Gibson DG, Palladino G, Brito LA, Otten GR, Brazzoli M, Buccato S, Bonci A, et al. Rapidly produced SAM((R)) vaccine against H7N9 influenza is immunogenic in mice. Emerg Microbes Infect 2013; 2:e52; PMID:26038486; http://dx.doi.org/10.1038/emi.2013.54
206. Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC). (2013). Clinical Trial Phase I
207. Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease. (2009). Clinical Trial Phase II
208. Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer. (2013). Clinical Trial Phase II
209. An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate Risk Patients With Prostate Cancer. (2014). Clinical Trial Phase II
210. IVAC MUTANOME Phase I Clinical Trial. (2014). Clinical Trial Phase I
211. Heidenreich R, Jasny E, Kowalczyk A, Lutz J, Probst J, Baumhof P, Scheel B, Voss S, Kallen KJ, Fotin-Mleczek M. A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile. Int J Cancer 2015; 137:372-84; PMID:25530186; http://dx.doi.org/10.1002/ijc.29402
212. CureVac Press Release. (http://www.curevac.com/fileadmin/curevac.de/media/Content/Newsroom/20151221_CureVac_Press_release_JP_Morgan.pdf). 2015
213. Islam MA, Reesor EK, Xu Y, Zope HR, Zetter BR, Shi J. Biomaterials for mRNA delivery. Biomater Sci 2015; 3:1519-33; PMID:26280625; http://dx.doi.org/10.1039/C5BM00198F
214. Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, Cu Y, Beard CW, Brito LA, Krucker T, et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A 2012; 109:14604-9; PMID:22908294; http://dx.doi.org/10.1073/pnas.1209367109
215. Rodriguez-Gascon A, del Pozo-Rodriguez A, Solinis MA. Development of nucleic acid vaccines:use of self-amplifying RNA in lipid nanoparticles. Int J Nanomedicine 2014; 9:1833-43; PMID:24748793; http://dx.doi.org/10.2147/IJN.S39810
216. Xu J, Luft JC, Yi X, Tian S, Owens G, Wang J, Johnson A, Berglund P, Smith J, Napier ME, et al. RNA replicon delivery via lipid-complexed PRINT protein particles. Mol Pharm 2013; 10:3366-74; PMID:23924216; http://dx.doi.org/10.1021/mp400190z
217. Pascolo S. The messenger's great message for vaccination. Expert Rev Vaccines 2015; 14:153-6; PMID:25586101; http://dx.doi.org/10.1586/14760584.2015.1000871
218. Hattinger E, Scheiblhofer S, Roesler E, Thalhamer T, Thalhamer J, Weiss R. Prophylactic mRNA Vaccination against Allergy Confers Long-Term Memory Responses and Persistent Protection in Mice. J Immunol Res 2015; 2015:797421; PMID:26557723; http://dx.doi.org/10.1155/2015/797421
219. Nelson HS, Oppenheimer J, Vatsia GA, Buchmeier A. A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract. J Allergy Clin Immunol 1993; 92:229-36; PMID:8349933; http://dx.doi.org/10.1016/0091-6749(93)90166-D
220. Roesler E, Weiss R, Weinberger EE, Fruehwirth A, Stoecklinger A, Mostbock S, Ferreira F, Thalhamer J, Scheiblhofer S. Immunize and disappear-safety-optimized mRNA vaccination with a panel of 29 allergens. J Allergy Clin Immunol 2009; 124:1070-7 e1-11; PMID:19665781; http://dx.doi.org/10.1016/j.jaci.2009.06.036
221. Ball T, Sperr WR, Valent P, Lidholm J, Spitzauer S, Ebner C, Kraft D, Valenta R. Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur J Immunol 1999; 29:2026-36; PMID:10382766; http://dx.doi.org/10.1002/(SICI)1521-4141(199906)29:06%3c2026::AID-IMMU2026%3e3.0.CO;2-2
222. Van Ree R, Van Leeuwen WA, Dieges PH, Van Wijk RG, De Jong N, Brewczyski PZ, Kroon AM, Schilte PP, Tan KY, Simon-Licht IF, et al. Measurement of IgE antibodies against purified grass pollen allergens (Lol p 1, 2, 3 and 5) during immunotherapy. Clin Exp Allergy 1997; 27:68-74; PMID:9117883; http://dx.doi.org/10.1046/j.1365-2222.1997.d01-416.x
223. Stafforst T, Schneider MF. An RNA-deaminase conjugate selectively repairs point mutations. Angewandte Chemie 2012; 51:11166-9; PMID:23038402; http://dx.doi.org/10.1002/anie.201206489
224. Schneider MF, Wettengel J, Hoffmann PC, Stafforst T. Optimal guideRNAs for re-directing deaminase activity of hADAR1 and hADAR2 in trans. Nucleic Acids Res 2014; 42:e87; PMID:24744243; http://dx.doi.org/10.1093/nar/gku272
225. Montiel-Gonzalez MF, Vallecillo-Viejo I, Yudowski GA, Rosenthal JJ. Correction of mutations within the cystic fibrosis transmembrane conductance regulator by site-directed RNA editing. Proc Natl Acad Sci U S A 2013; 110:18285-90; PMID:24108353; http://dx.doi.org/10.1073/pnas.1306243110
226. Bass BL. RNA editing by adenosine deaminases that act on RNA. Annu Rev Biochem 2002; 71:817-46; PMID:12045112; http://dx.doi.org/10.1146/annurev.biochem.71.110601.135501
227. Nishikura K. Functions and regulation of RNA editing by ADAR deaminases. Annu Rev Biochem 2010; 79:321-49; PMID:20192758; http://dx.doi.org/10.1146/annurev-biochem-060208-105251
228. Vogel P, Stafforst T. Site-directed RNA editing with antagomir deaminases–a tool to study protein and RNA function. ChemMedChem 2014; 9:2021-5; PMID:24954543; http://dx.doi.org/10.1002/cmdc.201402139
229. Vogel P, Schneider MF, Wettengel J, Stafforst T. Improving site-directed RNA editing in vitro and in cell culture by chemical modification of the guideRNA. Angewandte Chemie 2014; 53:6267-71; PMID:24890431; http://dx.doi.org/10.1002/anie.201402634
230. Hanswillemenke A, Kuzdere T, Vogel P, Jékely G, Stafforst T. Site-Directed RNA Editing in Vivo Can Be Triggered by the Light-Driven Assembly of an Artificial Riboprotein. J Am Chem Soc 2015; 137:15875-81; PMID:26594902; http://dx.doi.org/10.1021/jacs.5b10216
231. Zhao X, Yu Y-T. Targeted pre-mRNA modification for gene silencing and regulation. Nat Methods 2008; 5:95-100; PMID:18066073; http://dx.doi.org/10.1038/nmeth1142
232. Kole R, Krainer AR, Altman S. RNA therapeutics:beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 2012; 11:125-40; PMID:22262036; http://dx.doi.org/10.1038/nrd3625
233. Blanc V, Davidson NO. C-to-U RNA editing:mechanisms leading to genetic diversity. J Biol Chem 2003; 278:1395-8; PMID:12446660; http://dx.doi.org/10.1074/jbc.R200024200
234. Liu N, Pan T. N6-methyladenosine-encoded epitranscriptomics. Nat Struct Mol Biol 2016; 23:98-102; PMID:26840897; http://dx.doi.org/10.1038/nsmb.3162
235. Machnicka MA, Milanowska K, Oglou OO, Purta E, Kurkowska M, Olchowik A, Januszewski W, Kalinowski S, Dunin-Horkawicz S, Rother KM, et al. MODOMICS:a database of RNA modification pathways—2013 update. Nucleic Acids Res 2013; 41:D262-D7; PMID:23118484; http://dx.doi.org/10.1093/nar/gks1007
236. Muttach F, Rentmeister A. A Biocatalytic Cascade for Versatile One‐Pot Modification of mRNA Starting from Methionine Analogues. Angewandte Chemie International Edition 2016; 55:1917-20; http://dx.doi.org/10.1002/anie.201507577
237. Vickers TA, Wyatt JR, Burckin T, Bennett CF, Freier SM. Fully modified 2′ MOE oligonucleotides redirect polyadenylation. Nucleic Acids Res 2001; 29:1293-9; PMID:11238995; http://dx.doi.org/10.1093/nar/29.6.1293
238. Xiong Y, Steitz TA. Mechanism of transfer RNA maturation by CCA-adding enzyme without using an oligonucleotide template. Nature 2004; 430:640-5; PMID:15295590; http://dx.doi.org/10.1038/nature02711
239. Cho HD, Verlinde CL, Weiner AM. Reengineering CCA-adding enzymes to function as (U, G)-or dCdCdA-adding enzymes or poly (C, A) and poly (U, G) polymerases. Proc Natl Acad Sci U S A 2007; 104:54-9; PMID:17179213; http://dx.doi.org/10.1073/pnas.0606961104
240. Trippe R, Guschina E, Hossbach M, Urlaub H, Lührmann R, Benecke B-J. Identification, cloning, and functional analysis of the human U6 snRNA-specific terminal uridylyl transferase. RNA 2006; 12:1494-504; PMID:16790842; http://dx.doi.org/10.1261/rna.87706
241. Martin G, Keller W. RNA-specific ribonucleotidyl transferases. RNA 2007; 13:1834-49; PMID:17872511; http://dx.doi.org/10.1261/rna.652807
242. Zamecnik PC, Raychowdhury MK, Tabatadze DR, Cantiello HF. Reversal of cystic fibrosis phenotype in a cultured Δ508 cystic fibrosis transmembrane conductance regulator cell line by oligonucleotide insertion. Proc Natl Acad Sci U S A 2004; 101:8150-5; PMID:15148387; http://dx.doi.org/10.1073/pnas.0401933101
243. Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation. (2015). Clinical Trial Phase I
244. Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients. (2015). Clinical Trial Phase IB
245. Open Label, Extension Study of PRO044 in Duchenne Muscular Dystrophy (DMD). (2014). Clinical Trial Phase II
246. Phase IIb Study of PRO045 in Subjects With Duchenne Muscular Dystrophy. (2013). Clinical Trial Phase 2B
247. A Phase I/II Study of PRO053 in Subjects With Duchenne Muscular Dystrophy (DMD). (2013). Clinical Phase Trial I/II
248. Study of SRP-4045 and SRP-4053 in DMD Patients (ESSENCE). (2015). Clinical Trial Phase III
249. A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects. (2015). Clinical Trial Phase I
250. RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID (TNBC-MERIT). (2014). Clinical Trial Phase I
251. A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients. (2015). Clinical Trial Phase I